AstraZeneca reports positive trials for kidney drug
AstraZeneca
11,988.00p
16:40 26/04/24
AstraZeneca on Friday reported clinical trials of its roxadustat drug for patients with anaemia from chronic kidney disease had significantly increased red haemoglobin levels.
FTSE 100
8,139.83
17:09 26/04/24
FTSE 350
4,470.09
16:59 26/04/24
FTSE All-Share
4,423.59
17:14 26/04/24
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
'Anaemia is a common, serious condition among patients with chronic kidney disease,' said AstraZeneca executive vice-president of bioharmaceuticals research and development Mene Pangalos.
'It occurs when the body has fewer healthy red blood cells than normal and low levels of haemoglobin, which may leave patients fatigued and short of breath.'
Pangalos said results from the trials “reinforce the potential role that roxadustat could play in increasing haemoglobin levels and managing anaemia, which is often underdiagnosed and undertreated”.